EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment.

https://escholarship.org/uc/item/6np8x37p

Annals of oncology : official journal of the European Society for Medical Oncology, 26(2)

0923-7534

Whelan, JS
Bielack, SS
Marina, N
et al.

2015-02-01

10.1093/annonc/mdu526

Peer reviewed
EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment†

J. S. Whelan1, S. S. Bielack2, N. Marina3, S. Smeland4,5, G. Jovic6, J. M. Hook6, M. Krailo7, J. Anninga8, T. Butterfass-Bahloul9, T. Böhling10, G. Calaminus11, M. Capra12, C. Deffenbaugh13, C. Dhooge14, M. Eriksson15, A. M. Flanagan16,17, H. Gelderblom8, A. Goorin18, R. Gorlick19, G. Gosheger20, R. J. Grimer21, K. S. Hall22, K. Helmke23, P. C. W. Hogendoorn8, G. Jundt24, L. Kager25, T. Kuehne26, C. C. Lau27, G. D. Letson28, J. Meyer29, P. A. Meyers30, C. Morris30,31, H. Motti32, H. Nade33, R. Nagarajan34, R. L. Randall35, P. Schomberg36, R. Schwarz37, L. A. Teot38, M. R. Sydes6*,† & M. Bernstein29,† on behalf of the EURAMOS collaborators§

1Department of Oncology, University College Hospital, London, UK; 2Cooperative Osteosarcoma Study Group (COSS), Klinikum Stuttgart - Olphospital, Stuttgart, Germany; 3Stanford University Medical Center, Pediatric Hematology/Oncology, Palo Alto, USA; 4Division of Cancer, Surgery and Transplantation, and Scandinavian Sarcoma Group, Oslo University Hospital, Oslo; 5Institute for Clinical Medicine, University of Oslo, Oslo, Norway; 6Medical Research Council Clinical Trials Unit at University College London, London, UK; 7Children’s Oncology Group, Arcadia, USA; 8Department of Pediatrics and Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands; 9Center for Clinical Trials, University Hospital Münster, Münster, Germany; 10University of Helsinki and HUSLAB, Helsinki, Finland; 11University Hospital of Muenster, Muenster, Germany; 12Our Lady’s Children’s Hospital, Dublin, Ireland; 13Lucile Packard Children’s Hospital Stanford, Palo Alto, USA; 14University Hospital Ghent, Gent, Belgium; 15Skane University Hospital, Lund University, Lund, Sweden; 16Royal National Orthopaedic Hospital, Stanmore, UK; 17Cancer Institute, University College London, London, UK; 18Diana-Farber Cancer Institute, Boston; 19Section of Pediatric Hematology/Oncology, Montefiore Medical Center, Bronx, USA; 20Department of General Orthopedics and Tumor Orthopedics, University Hospital Muemter, Muemter, Germany; 21Royal Orthopaedic Hospital, Birmingham, UK; 22Department of Oncology, Oslo University Hospital, Norwegian Radium Hospital, Scandinavian Sarcoma Group, Oslo, Norway; 23Department of Pediatric Radiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; 24Bone Tumor Reference Center at the Institute of Pathology, University Hospital Basel, Basel, Switzerland; 25St Anna Children’s Hospital Vienna, Austria; 26University Children’s Hospital Basel, Basel, Switzerland; 27Texas Children’s Cancer Center, Baylor College of Medicine, Houston; 28H. Lee Moffitt Cancer Centre & Research Institute, Tampa; 29Children’s Hospital of Philadelphia, University of Pennsylvania School of Medicine, Philadelphia; 30Memorial Sloan-Kettering Cancer Center, New York; 31Orthopedic Surgery, Johns Hopkins, Baltimore, USA; 32Department of Pediatric Hematology Oncology, University Hospital, Prague, Czech Republic; 33British Columbia Children’s Hospital, University of British Columbia, Vancouver, Canada; 34Cincinnati Children’s Hospital Medical Center, Cincinnati; 35Primary Children’s Hospital and Huntsman Cancer Institute, University of Utah, Salt Lake City; 36Mayo Clinic, Rochester, USA; 37Department of Radiation Oncology, Medical Center Hamburg-Eppendorf, Hamburg, Germany; 38Department of Pathology, Boston Children’s Hospital, Boston, USA; 39WK Health Center, Dalhousie University, Halifax, Canada

Received 21 July 2014; revised 26 October 2014; accepted 6 November 2014

Background: Four international study groups undertook a large study in resectable osteosarcoma, which included two randomised controlled trials, to determine the effect on survival of changing post-operative chemotherapy based on histological response.

Patients and methods: Patients with resectable osteosarcoma aged ≤40 years were treated with the MAP regimen, comprising pre-operatively of 5 week cycles of cisplatin 120 mg/m², doxorubicin 75 mg/m², methotrexate 12 g/m² × 2 (MAP) and post-operatively two further cycles of MAP and two cycles of just MA. Patients were randomised after surgery. Those with ≥10% viable tumour in the resected specimen received MAP or MAP with ifosfamide and etoposide. Those with <10% viable tumour were allocated to MAP or MAP followed by pegylated interferon. Longitudinal evaluation of quality of life was undertaken.

Results: Recruitment was completed to the largest osteosarcoma study to date in 75 months. Commencing March 2005, 2260 patients were registered from 326 centres across 17 countries. About 1334 of 2260 registered patients (59%) were randomised. Pre-operative chemotherapy was completed according to protocol in 94%. Grade 3–4 neutropenia affected 83%

*Correspondence to: Mr Matthew R. Sydes, MRC Clinical Trials Unit at UCL, Aviation House, 125 Kingsway, London WC2B 6NH, UK. Tel: +44-207-6704798; E-mail: m.sydes@ucl.ac.uk
†Presented in part at American Society of Clinical Oncology Annual Meeting Chicago 2012.
‡Both authors contributed equally.
§See supplementary Material, available at Annals of Oncology online.
of cycles and 59% were complicated by infection. There were three (0.13%) deaths related to pre-operative chemotherapy. At definitive surgery, 50% of patients had at least 90% necrosis in the resected specimen.

Conclusions: New models of collaboration are required to successfully conduct trials to improve outcomes of patients with rare cancers; EURAMOS-1 demonstrates achievability. Considerable regulatory, financial and operational challenges must be overcome to develop similar studies in the future. The trial is registered as NCT00134030 and ISRCTN 67613327.

Key words: osteosarcoma, randomised controlled trial, trial conduct, international collaboration

introduction

Osteosarcoma is the commonest primary bone cancer affecting young people with an overall age-standardised incidence rate of 5.2 cases/million [1]. Cure of osteosarcoma in a proportion of patients was consistently reported first in the 1970s, achieved through the combination of surgical extirpation of the primary tumour with multi-drug chemotherapy. The results were further improved during the next decade, but since then, no clinically significant advances have been made in survival, although more patients access combination chemotherapy within and outside trials.

In 2001, four clinical study groups agreed to collaborate to conduct osteosarcoma studies more rapidly. EURAMOS (European and American Osteosarcoma Studies) was formed from the Children’s Oncology Group (COG), Cooperative Osteosarcoma Study Group (COSS) of the German Society for Pediatric Oncology and Hematology (GPOH), European Osteosarcoma Intergroup (EOI) and Scandinavian Sarcoma Group (SSG).

The EURAMOS group aimed to improve outcomes in osteosarcoma, principally through large international, collaborative randomised, controlled trials (RCTs). Additional objectives were to facilitate biological research in osteosarcoma, more rapidly identify new therapeutic approaches and develop a common understanding and methodologies for staging, pathology and other aspects of disease management [2].

The first study, EURAMOS-1, began recruitment in 2005 and closed registration in June 2011. Good histological response, assessed in the resected tumour, has been associated with improved survival [3–5]. Therefore, this study addressed separate treatment questions based on histological response. EURAMOS-1 was notable for addressing randomised questions in a rare cancer on an unprecedented scale and for launching at a time of profound change to European legislation related to trial regulation and governance [6]. We describe the study, its population and the initial treatment of 2260 registered patients.

methods

patients

We designed a clinical trial to include patients with newly diagnosed localised or metastatic osteosarcoma (see supplementary Material, available at Annals of Oncology online) of the extremity or axial skeleton deemed to be suitable for complete resection of all disease sites. Patients were aged ≤40 years at diagnostic biopsy and had to both register on the study and start chemotherapy within 30 days after diagnostic biopsy. Patients required adequate bone marrow function (neutrophils ≥0.5 × 10⁹/l or WBC ≥3 × 10⁹/l; platelet count >100 × 10⁹/l); renal function (glomerular filtration rate ≥70 ml/min/1.73 m²); liver function (bilirubin ≤1.5 × upper limit of normal); cardiac function (shortening fraction ≥28% or ejection fraction ≥50%) and performance status ( Karnofsky score ≥60; WHO performance status ≤2; or Lansky score ≥60%). Standard staging and organ function investigations were undertaken.

Diagnostic biopsies were to be examined by local institutional pathologists and reviewed by each study group’s reference pathologists.

study design

Figure 1 shows the design with randomisation defined by histological response in the primary tumour after pre-operative chemotherapy. Response classification was dichotomised: ≥90% necrosis (good response); <90% necrosis (poor response). Registered patients were offered randomisation when also had: completed two courses of cisplatin and doxorubicin pre-operatively; completed ≥2 (but ≤6) courses of methotrexate pre-surgery; recovered fully from prior therapy; no disease progression; undergone complete macroscopic resection of the primary tumour and undergone complete removal of all metastatic disease or this was planned and deemed feasible. Patients with good histological response had to be ≥5 years due to concerns of age-related toxicity from interferon [7]. Data collection including registration characteristics and reports on pre-operative chemotherapy, surgery and pathology had to be received by the randomising data centre. Consent was obtained according to national regulations. Supp_Appendix_B (supplementary Material, available at Annals of Oncology online) describes the study organisation.

Figure 1. EURAMOS-1 study design.
Eligible, consenting patients with good histological response were randomised to complete six cycles of MAP or MAP followed by maintenance pegylated interferon α-2b (Ifn; Merck) at 0.5–1.0 µg/kg/week to 24 months after starting chemotherapy. Eligible, consenting patients with poor histological response were randomised to continue standard chemotherapy with MAP or to MAP/IE over 28 weeks, a schedule designed to deliver the same total doses as post-operative MAP with additional ifosfamide and etoposide (IE), agents previously demonstrating activity in osteosarcoma [9]. Ifosfamide 3000 mg/m² ×3 days, total dose 9 g/m², was given with doxorubicin in (IE), agents previously demonstrating activity in osteosarcoma [9].

The protocol detailed dose modifications to account for toxicity for all treatments. Granulocyte growth factors were recommended but not mandated. Dexamethasone could be used at investigators’ discretion for reduced cardiac function remaining in the normal range; this applied throughout in North America but was withdrawn by the European Medicines Agency in 2011.

Response assessment was required to determine suitability for surgery and to exclude progression (see supplementary Material, available at Annals of Oncology online).

quality-of-life evaluation
Quality of life (QL) was assessed using self- and parent-completed questionnaires to determine short- and long-term impacts. For patients ≥16 years, QL was assessed using EORTC QLQ-C30 questionnaire [10]. Patients <16 years in COG centres answered the generic PedsQL questionnaire, and in Europe, PEDQOL [11, 12]. The initial QL assessment was at week 5, then 3 months after definitive surgery, at 18 months and 3 years after commencing therapy.

outcome measures
The primary outcome measure was event-free survival (EFS), defined as time from randomisation to the first of: detection of local recurrence or metastases, progression of metastatic disease, detection of secondary malignancy or death from any cause. EFS was chosen because prevention of first recurrence is the principal goal of adjuvant treatment of osteosarcoma, given the low rate of survival after first recurrence. Furthermore, treatment of recurrence is heterogeneous; treatment guidance for relapse accompanied the protocol, but sites’ existing standard practice was accepted. Secondary outcome measures were overall survival (OS), toxicity and QL. Toxicity was assessed using CTCAE version 3.0 [13].

sample size calculations
We assumed 70% 3-year EFS on MAP for good response and 45% for poor response, timed from randomisation. Each sample size was based on 5% significance level and 80% power. The Good Response randomisation needed 147 EFS events to detect improved 3-year EFS from 70% to 80%, i.e., hazard ratio (HR) = 0.63 [14]. Five-year survival was estimated as 70% so solution needed 147 EFS events to detect improved 3-year EFS from 70% to 80%, two-sided significance level and 80% power. The Good Response randomisation needed 147 EFS events to detect improved 3-year EFS from 70% to 80%, i.e., hazard ratio (HR) = 0.63 [14]. Five-year survival was estimated as 70% so long-term analyses for survival were planned for when 147 deaths are reported, for the same relative and absolute improvements. For poor response, 378 events were targeted to detect improved 3-year EFS and 5-year OS from 45% to 55% (HR = 0·75).

We anticipated 45% (567) randomised patients would have good response and 55% (693) poor response [8]. We planned to register ~1400 patients over 3.5 years to randomise 1260, assuming 10% non-randomisation for eligibility or non-consent. The observed non-randomisation rate was higher over 3.5 years to randomise 1260, assuming 10% non-randomisation for ineligibility or non-consent. The observed non-randomisation rate was higher.

The registration target was increased to ~2000 patients.

statistical analysis
This paper describes the full, registered patient population, including all patients who signed the informed consent documents, up to the point of surgery. Standard descriptive statistics are used.
results

study participants

Between April 2005 and June 2011, 2260 patients from 326 sites in seventeen countries were registered (supplementary Figures S1 and S2, available at Annals of Oncology online); 1164 (52%) COG, 520 (23%) COSS, 457 (20%) EOI and 119 (5%) SSG. The majority of patients were aged 10–19 with localised tumours of the lower limb (Table 1) and conventional type osteosarcoma on histology (Table 2). Males comprised 59% (1330/2260) of the cohort; 355 (16%) had definite metastases, 161 (7%) possible and 1722 (77%) no metastases. Of 355 patients with definite metastases, 273 (77%) had lung mets only, 54 (15%) other mets only, 22 (6%) both lung and other and 5 (1%) definite-lung and possible other mets. Of 161 patients with possible metastases, 144 (89%) had possible lung metastases, 11 (7%) possible other mets. Of 161 patients with possible metastases, 144 (89%) had possible lung metastases, 11 (7%) possible other mets and 6 (4%) both. Table 1 shows baseline characteristics.

The eligibility criteria spanned children and adults ≤40 years old. We estimated accrual as a proportion of expected age-related incidence of osteosarcoma in the UK to address whether participation was equally likely within the study age range. In all groups, the proportion recruited from the estimated population fell from age ≥15 yrs in females and 19 yrs in males, such that ~1/3 of potentially eligible patients were not registered (supplementary Figure S3, available at Annals of Oncology online). Figure 3 shows the CONSORT diagram.

randomisation

Randomisation was offered to eligible registered patients with reported histological response. For those with reported good response, 69% (716/1040) accepted the randomisation and for poor response, 58% (617/1059); one patient with good response was erroneously randomised to the poor response cohort and allocated MAP. The overall randomisation rate was 64% (1334/2100) for patients with known histological response.

There was some variability in proportion randomised between groups: COSS 363/520 (70%), SSG 82/119 (69%), EOI 276/457 (60%) and COG 613/1164 (53%) (supplementary Table S2, available at Annals of Oncology online). Patients aged 20–29 years were less frequently randomised (106/199, 53%) than those 5–19 years (1194/1995, 60%) or >30 years (32/53, 60%). The main reason recorded for non-randomisation was absence of consent (413/2260, 18%). Progression prior to surgery was recorded in 176 patients (8%). Eighty-eight patients (4%) could not be randomised because of late reporting of histology and 67 (3%) for incorrect pre-operative chemotherapy. Patient characteristics for randomised and non-randomised patients and by histological response are shown in Table 1.

histology

Diagnosis was confirmed by reference pathologists in 2160/2209 (98%) of registered patients (Table 2). The commonest histological subtype was conventional (92%, 2033/2209), followed by telangiectatic (4%, 96/2209), small cell (1%, 14/2209) and high-grade surface (1%, 29/2209). Thirty-one patients were deemed ineligible post-registration based on reference histological review of the biopsy. Biopsy details remain unavailable for 51 patients (2%). In 1917 patients with reference pathologist assessment of both diagnostic biopsy and resected specimen, the classification was different for 75 (4%) patients. Of these, 36/75 were re-classified as different subtypes of osteosarcoma, 13/75 as conventional, 13/75 as telangiectatic, 6/75 as high-grade surface osteosarcoma and 5/75 were ineligible.

Pathological assessment of histological response to pre-operative chemotherapy was available for 1975/2012 patients; 979 reported a good response and 996 a poor response. The response rate of good histological response to MAP was 50% overall, ranging from 46% (433/949) COG, to 53% COSS (265/499), 53% SSG (58/110) and 54% EOI (223/417).

chemotherapy

Ninety-four percent registered patients (2123/2248) completed two cycles of MAP pre-operatively. Median received pre-operative dose for doxorubicin was 149 mg/m2 (target 150 mg/m2), 239 mg/m2 cisplatin (target 240 mg/m2) and 46.8 g/m2 high-dose methotrexate (target 48 g/m2). Median time from registration in EURAMOS-1 to starting chemotherapy was 0 days [interquartile range (IQR) -2; 0]. Median time from start of chemotherapy to surgery was 82 days (IQR 76; 90). Median time from surgery to starting post-operative chemotherapy for randomised patients was 18 days (IQR 14; 24).

The pre-operative toxicities reported were as expected. Table 3 shows the worst reported toxicity. CTCAE grade 3–4 toxicity was common: 1863/2234 (83%) neutropenia; 1292/2237 (58%) infective complications; 1122/2238 (50%) thrombocytopenia; 544/1989 (27%) mucositis; grade 1 or 2 mucositis was reported in a further 21% (427/1989) and 28% (557/1989), respectively. Severe renal, neurological and left ventricular dysfunctions were uncommon.

There were three treatment-related deaths (3/2260, 0.13%) during the pre-operative period, two from infective complications and one from toxic epidermal necrolysis secondary to methotrexate.

surgery

The amputation rate, including rotationplasty, was 17% (346/2054), ranging from 16% (169/1045, COG) to 19% (22/114, SSG) (Table 4). Macroscopic clearance of the primary tumour was reported in 99% (2035/2054), ranging from 16% (169/1045, COG) to 19% (22/114, SSG) (Table 4). Macroscopic clearance of the primary tumour was reported in 99% (2035/2051). There were three post-operative deaths: one patient died from embolic complications on the third post-operative day, a second from pneumonia with respiratory failure on day 29 and a third from infection complicated by multisystem failure 48 days after surgery.

data completeness and follow-up

Long-term event data were sought in all patients, regardless of randomisation. In 15 February 2013, 1455/1566 (93%) had data within the previous 14 months; death and loss to follow-up were reported in 526/2260 and 168/2260 patients, respectively. Long-term event data from the full cohort, including second malignancy data, will be reported with further follow-up.

discussion

Osteosarcoma therapy was revolutionised by the introduction of adjuvant combination chemotherapy, in the 1970s, but has
### Table 1. Baseline characteristics at registration

| Response                  | Randomised |               | Not randomised |               | Overall |          |
|---------------------------|------------|---------------|----------------|---------------|---------|----------|
|                           | Good       | Poor          | Good           | Poor          | Not known | N   |
|                           | N          | %             | N              | %             | N        |
| Sex                       |            |               |                |               |          |         |
| Male                      | 421        | 59            | 365            | 59            | 190      | 69      | 1330    | 59 |
| Female                    | 295        | 41            | 253            | 41            | 134      | 41      | 930     | 41 |
| Missing                   | 0          | n/a           | 0              | n/a           | 0        | n/a     | 0       | n/a|
| Age at registration       |            |               |                |               |          |         |
| 0–4                       | 1          | 0             | 0              | 0             | 0        | 0       | 11      | 0  |
| 5–9                       | 102        | 14            | 94             | 15            | 48       | 15      | 310     | 14 |
| 10–14                     | 305        | 43            | 217            | 35            | 130      | 40      | 878     | 39 |
| 15–19                     | 258        | 36            | 218            | 35            | 113      | 35      | 809     | 36 |
| 20–24                     | 28         | 4             | 52             | 8             | 19       | 6       | 153     | 7  |
| 25–29                     | 11         | 2             | 15             | 2             | 5        | 2       | 46      | 2  |
| 30–34                     | 1          | 0             | 9              | 1             | 3        | 1       | 19      | 1  |
| 35–39                     | 10         | 1             | 11             | 2             | 0        | 0       | 30      | 1  |
| 40                        | 0          | 0             | 0              | 0             | 0        | 0       | 0       | 0  |
| Median (quartiles)        |            |               |                |               |          |         |
| Min–max                   | 14 (11, 16)| 14 (11, 17)   | 14 (11, 16)    | 15 (12, 17)   | 15 (11, 17)| 14 (11, 17)|        |    |
| Site and location          |            |               |                |               |          |         |
| Proximal femur or humerus  | 83         | 12            | 77             | 13            | 44       | 14      | 293     | 13 |
| Other limb site           | 617        | 86            | 508            | 82            | 265      | 84      | 1837    | 82 |
| Axial or skeletal         | 16         | 2             | 31             | 5             | 7        | 2       | 108     | 5  |
| Missing                   | 0          | n/a           | 2              | n/a           | 8        | n/a     | 22      | n/a|
| Pathological fracture     |            |               |                |               |          |         |
| No at diagnosis           | 629        | 88            | 545            | 89            | 272      | 86      | 1964    | 88 |
| Yes at diagnosis          | 86         | 12            | 69             | 11            | 44       | 14      | 273     | 12 |
| Missing                   | 1          | n/a           | 4              | n/a           | 8        | n/a     | 23      | n/a|
| Localised disease         |            |               |                |               |          |         |
| Yes (no mets)             | 567        | 79            | 491            | 80            | 239      | 76      | 1722    | 77 |
| Possible mets             | 63         | 9             | 48             | 8             | 19       | 6       | 161     | 7  |
| No (yes mets)             | 86         | 12            | 76             | 12            | 58       | 18      | 355     | 16 |
| Missing                   | 0          | n/a           | 3              | n/a           | 8        | n/a     | 22      | n/a|
| Lung metastases           |            |               |                |               |          |         |
| No                        | 583        | 81            | 505            | 82            | 247      | 78      | 1782    | 80 |
| Possibly                  | 62         | 9             | 46             | 7             | 16       | 5       | 156     | 7  |
| Yes                       | 71         | 10            | 64             | 10            | 53       | 17      | 301     | 13 |
| Missing                   | 0          | n/a           | 3              | n/a           | 8        | n/a     | 21      | n/a|
| Other metastases          |            |               |                |               |          |         |
| No                        | 691        | 97            | 590            | 96            | 304      | 97      | 2140    | 96 |
| Possibly                  | 5          | 1             | 8              | 1             | 4        | 1       | 2       | 2  |
| Yes                       | 20         | 3             | 18             | 3             | 7        | 2       | 76      | 3  |
| Missing                   | 0          | n/a           | 2              | n/a           | 9        | n/a     | 22      | n/a|
| Duration of symptoms (days)|            |               |                |               |          |         |
| Median (quartiles)        | 8 (4, 13)  | 8 (4, 14)     | 8 (4, 12)      | 10 (6, 16)    | 9 (6, 16) | 8 (4, 14) |        |    |
| Min–max                   | 0–78       | 0–312         | 0–104          | 0–260         | 0–104    | 0–312   |        |    |
| Missing                   | 85         | n/a           | 68             | n/a           | 43       | n/a     | 285     | n/a|
| Group                     |            |               |                |               |          |         |
| COG                       | 300        | 42            | 313            | 51            | 180      | 56      | 1164    | 52 |
| COSS                      | 206        | 29            | 157            | 25            | 60       | 19      | 520     | 23 |
| EOI                       | 161        | 22            | 115            | 19            | 73       | 23      | 457     | 20 |
| SSG                       | 49         | 7             | 33             | 5             | 11       | 3       | 119     | 5  |
| Total                     | 716        | 100           | 618            | 100           | 324      | 100     | 2260    | 100|
improved little since. The cost of seeking cure is exceptionally high as patients receive particularly complex and toxic chemotherapy regimens, plus disabling surgery. The single new treatment which has emerged, mifamurtide (MTP-PE), has been the subject of considerable controversy and its availability varies internationally, due to disagreements about interpretation of the available clinical data and cost.

While many studies have been undertaken for osteosarcoma, they are often characterised by being non-randomised or, if randomised, by their long accrual periods [15–18]. This was the background against which we joined together to attempt to develop new paradigms for treating this disease.

The EURAMOS group chose to undertake a large cohort study, embedding two randomised comparisons as our first collaboration [6]. The two questions chosen for this first study stratified post-operative treatment according to the histologically assessed response to pre-operative chemotherapy. It assessed maintenance therapy in patients with a better prognosis (Good Response) [19] and intensification in patients with poorer prognosis (Poor Response) [9, 20–22]. These important questions were amenable to a relatively simple trial design. However, the agents chosen highlight the paucity of new or investigational products appropriate to include in phase III trials.

EURAMOS-1 has been successfully executed. The study was developed through a commitment to collaboration between four well-established study groups. With 1334 patients with resectable osteosarcoma randomised, it doubled the size of the previous largest RCT in this population and accrual was completed in around 6 years. Other indicators of quality and safety for a trial on this scale are reassuring. Concordance with protocol chemotherapy was excellent. Toxicities were consistent with previous experience of these agents. The treatment-related death
In other areas, the study has highlighted where improvement is needed. This was the first publicly-funded pan-European clinical trial to be activated after European countries implemented the European Clinical Trials Directive, which created new challenges [23]. There were limits to the accessibility of the trial for osteosarcoma patients. We were unable to open EURAMOS-1 in some countries that wished to participate either because of regulatory constraints or insufficient funding. Moreover, even though we used age eligibility criteria which allowed inclusion of all patients aged <40 years, the proportion of potentially eligible patients fell with increasing age beginning from late teenage years, a phenomenon consistent with accrual rates seen for other cancers in young adults [24, 25].

The feasibility of delivering intensive chemotherapy for a rare cancer in multiple centres within a Good Clinical Practice framework is amply demonstrated here. However, it is also clear that the treatment burden of MAP is exceptionally high, reflected in levels of grade 3–4 haematological and non-haematological toxicity. While the link between increased toxicity and improved survival from osteosarcoma remains to be unravelled [26], future approaches must look to reduce this burden as well as improve efficacy.

At the time of trial planning, few data were available to guide a sample size calculation to accurately estimate randomisation rates and these were markedly lower than expected, which contributed to a decision to expand registration targets from 1400 to over 2000. Information collected on reasons for non-randomisation has been relatively non-informative but anecdotally, young people expressed a reluctance to risk allocation to experimental treatments that were substantially longer than the standard MAP schedule. Further investigation of this important area is needed [27]. Greater patient involvement at the design stage may help in the future.

First results of the Good Response randomisation have been presented orally [28], with a clear demonstration that large-scale practice-changing randomised, controlled trials can be undertaken in rare cancers by extending the traditional boundaries of collaboration. From EURAMOS-1, we are growing a wider collaboration with groups willing to work together. A successor study has not yet emerged despite willingness by investigators and other trials groups joining the collaboration to face the

| Table 3. Worst pre-operative MAP toxicity |
|------------------------------------------|
| Worst toxicity grade with pre-operative MAP | Randomised | Not randomised | Overall |
|                                          | Good | Poor | N | % | N | % | N | % | N | % |
| Grade 0                                  | 7    | 10  | 2 |  | 4 | 1  | 3 | 1 | 8 | 5 |
| Grade 1                                  | 12   | 8   | 1 |  | 5 | 2  | 9 | 2 | 5 | 3 |
| Grade 2                                  | 19   | 40  | 6 |  | 9 | 3  | 18| 4 | 9 | 6 |
| Grade 3                                  | 109  | 79  | 13|  | 36| 11 | 79| 18| 28| 18 |
| Grade 4                                  | 569  | 480 | 78|  | 267| 82 | 331| 75| 95| 59 |
| Grade 5                                  | 0    | 0   | 0 |  | 1 | 0  | 0 | 0 | 2 | 1 |
| Not assessed                             | 0    | n/a | 1 | n/a | 1 | n/a | 1 | n/a | 1 | n/a |
| Not reported on CRF                      | 0    | n/a | 0 | n/a | 1 | n/a | 1 | n/a | 12| n/a |
| Total                                    | 716  | 100 | 618| 100| 324| 100| 442| 100| 160| 100| 2260| 100|

Three deaths were treatment-related (two from infective complications and one from toxic epidermal necrolysis secondary to methotrexate) and three occurred after surgery.

Percentages exclude the ‘not assessed’ and ‘not reported’ rows.

Excludes three deaths occurred after surgery. Of those patients, one Good Responder had worst toxicity of grade 1; one poor responder had worst toxicity of grade 3 and one person with unknown histological response had a worst toxicity of grade 4.

| Table 4. Surgical details |
|--------------------------|
| Data source              | Total |
|                          | N   | %  |
| Surgical data            |     |    |
| Received                 | 2054| 91 |
| Not received             | 206 | 9  |
| Pathological fracture at surgery |
| No                       | 1881| 92 |
| Yes                      | 169 | 8  |
| Missing on surgery form  | 4   | n/a|
| Surgical procedure       |     |    |
| Amputation               | 213 | 10 |
| Disarticulation          | 30  | 1  |
| Rotationplasty           | 103 | 5  |
| Resection + reconstruction | 1571| 77 |
| Resection only           | 91  | 4  |
| Other                    | 45  | 2  |
| Missing                  | 1   | n/a|
| Macroscopic clearance achieved |
| Yes                      | 2035| 99 |
| No, despite surgery      | 16  | 1  |
| Missing                  | 3   | n/a|
| Total                    | 2054| 100|

rate of 0.18% from pre-operative chemotherapy is at the lower end of the range previously reported.
formidable regulatory and financial challenges which must be overcome. The absence of testable new innovations in this disease is a cause for major concern and even more apparent now we have established a successful test platform.

acknowledgements
We acknowledge the input of James Pickering, Nicola Joffe, Matthias Kevric, Benjamin Sorg, DooiJuen Villalluna, Caroline Wang, Martha Perisoglou, Leonardo Trani, Jenny Potratz, Dorothe Carre, Miriam Wilhelm, Katja Zils, Carmen Teske.

funding
Acknowledgement of research support: EURAMOS-1 is an academic clinical trial funded through multiple national and international government agencies and cancer charities (see http://d212.219.75.232/euramos/euramos1_funders/default.asp).

disclosure
The authors have declared no conflicts of interest.

references
1. Whelan J, McTiernan A, Cooper N et al. Incidence and survival of malignant bone sarcomas in England 1979–2007. Int J Cancer 2011; 131: E508–E517.
2. Marina N, Bielack S, Whelan J et al. International collaboration is feasible in trials for rare conditions: the EURAMOS experience. Cancer Treat Res 2009; 152: 339–353.
3. Rosen G, Murphy ML, Huves AG et al. Chemotherapy, en bloc resection, and prosthetic bone replacement in the treatment of osteogenic sarcoma. Cancer 1976; 37: 1–11.
4. Bacci G, Picci P, Ruggieri P et al. Primary chemotherapy and delayed surgery (neo-adjuvant chemotherapy) for osteosarcoma of the extremities. Cancer 1990; 65: 2539–2553.
5. Whelan JS, Jinks RC, McTiernan A et al. Survival from high-grade localised extremity osteosarcoma: combined results and prognostic factors from three European Osteosarcoma Intergroup randomised controlled trials. Ann Oncol 2012; 23: 1607–1616.
6. Marina N, Bielack S, Whelan J et al. International collaboration is feasible in trials for rare conditions: the EURAMOS experience. In Jaffe N, Bruoland OS, Bielack S (eds), Pediatric and Adolescent Osteosarcoma Series: Cancer Treatment and Research, Vol. 152. 2010; 339–354.
7. Barkow CF, Priebe CJ, Mulliken JB et al. Spastic diplegia as a complication of interferon alfa-2a treatment of hemangomas of infancy. J Pediatr 1998; 132: 527–530.
8. Meyers PA, Schwartz CL, Krailo M et al. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol 2005; 23: 2004–2011.
9. Goorin AM, Harris MB, Bernstein M et al. Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a Pediatric Oncology Group trial. J Clin Oncol 2002; 20: 426–433.
10. Aaronson NK, Ahmzadai B, Bergman B et al. The European Organization for Research and Treatment of Cancer QLC-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365–376.
11. Varni JW, Burwinkle TM, Katz ER et al. The PedsQL in pediatric cancer: reliability and validity of the Pediatric Quality of Life Inventory Generic Core Scales, Multi-dimensional Fatigue Scale, and Cancer Module. Cancer 2002; 94: 2106–2106.
12. Calaminus G, Weinspach S, Teske C, Gobel U. Quality of life in children and adolescents with cancer. First results of an evaluation of 49 patients with the PEGDOL questionnaire, Klin Padiatr 2000; 212: 211–215.
13. Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events, Version 3.0, DCTD, NCI, NIH, DHHS. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_archive:2006 (28 Nov 2014, date last accessed).
14. George SL, Desu MM. Planning the size and duration of a clinical trial studying the time to some critical event. J Chronic Dis 1974; 27: 15–24.
15. Ferrari S, Smeland S, Murceti M et al. Neoadjuvant chemotherapy with high-dose ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups. J Clin Oncol 2005; 23: 8845–8852.
16. Le Deley MC, Guinebretiere JM, Gentet JC et al. SFOP OS94: a randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients. Eur J Cancer 2007; 43: 752–761.
17. Lewis U, Nooli MA, Whelan J et al. Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase II trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst 2007; 99: 112–128.
18. Smeland S, Muller C, Abegard TA et al. Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII: prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders. Eur J Cancer 2003; 39: 488–494.
19. Whelan J, Patterson D, Perisoglou M et al. The role of interferons in the treatment of osteosarcoma. Pediatr Blood Cancer 2010; 54: 350–354.
20. Schwartz CL, Wisler LH, Devdias M et al. P9754 therapeutic intensification in non-metastatic osteosarcoma: a COG trial. J Clin Oncol (Meeting Abstracts) 2004; 22: abstr 8514.
21. Gentet JC, Brunat-Mentigny M, Demaille MC et al. Ifosfamide and etoposide in childhood osteosarcoma. A phase II study of the French Society of Paediatric Oncology. Eur J Cancer 1997; 33: 222–237.
22. Rosen G, Forscher C, Lovenbruun G et al. Synovial sarcoma. Uniform response of metastases to high dose ifosfamide. Cancer 1994; 73: 2506–2511.
23. Bielack SS. Osteosarcoma: time to move on? Eur J Cancer 2010; 46: 1942–1945.
24. Fern L, Davies S, Eden T et al. Rates of inclusion of teenagers and young adults in England into National Cancer Research Network clinical trials: report from the National Cancer Research Institute (NCR) Teenage and Young Adult Clinical Studies Development Group. Br J Cancer 2008; 99: 1967–1974.
25. Fern LA, Loxwoodowski JA, Coxon KM et al. Available, accessible, aware, appropriate, and acceptable: a strategy to improve participation of teenagers and young adults in cancer trials. Lancet Oncol 2014; 15: e341–e350.
26. McTiernan A, Jinks RC, Sydes MR et al. Presence of chemotherapy-induced toxicity predicts improved survival in patients with localised extremity osteosarcoma treated with doxorubicin and cisplatin: a report from the European Osteosarcoma Intergroup, Eur J Cancer 2012; 48: 703–712.
27. Pearce S, Lavender V, Brownson A et al. Perceptions of participants and professionals in bone sarcoma clinical trials: implications for study design and conduct. Eur J Cancer 2013; 49(suppl 2): A3819.
28. Bielack S, Smeland S, Whelan J et al. MAP plus maintenance pegylated interferon α-2b (MAPfri) versus MAP alone in patients with resectable high-grade osteosarcoma and good histologic response to preoperative MAP: first results of the EURAMOS-1 “good response” randomization. J Clin Oncol 2013; 31(suppl): LBA10504.